SHANGHAI, China, March 31, 2026
Abbisko Therapeutics has announced that its investigational FGFR4 inhibitor irpagratinib (ABSK-011) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for hepatocellular carcinoma (HCC), marking a significant regulatory milestone in the global development of targeted therapies for liver cancer. The designation highlights the drug’s potential to address a critical unmet medical need in patients with advanced HCC, particularly those with FGF19 overexpression, and provides key regulatory incentives to accelerate its development and commercialization.
EMA Orphan Drug Designation Boosts Clinical Development
The Orphan Drug Designation granted by the EMA recognizes irpagratinib’s potential clinical value in treating a rare and life-threatening condition, offering benefits such as protocol assistance, regulatory fee reductions, and up to 10 years of market exclusivity upon approval. This designation is expected to significantly support Abbisko’s regulatory strategy and accelerate the pathway toward European commercialization.
Irpagratinib is a highly selective, orally administered small-molecule FGFR4 inhibitor, designed to target the FGF19/FGFR4 signaling pathway, which plays a critical role in tumor growth and progression in a subset of liver cancer patients. The therapy is currently being evaluated in multiple global clinical trials, including studies as both monotherapy and in combination with targeted immunotherapies, reflecting its broad therapeutic potential.
Addressing Unmet Needs in Liver Cancer Treatment
Advertisement
Hepatocellular carcinoma remains one of the leading causes of cancer-related mortality worldwide, accounting for approximately 75–85% of primary liver cancer cases. Despite advances in treatment, effective second-line and later-line therapies remain limited, particularly for patients who do not respond to standard first-line treatments such as immune checkpoint inhibitors combined with anti-angiogenic therapies.
Notably, around 30% of HCC patients exhibit FGF19 overexpression, a biomarker associated with poor prognosis and reduced response to existing therapies. Currently, there are no approved therapies specifically targeting the FGFR4/FGF19 pathway, making irpagratinib a promising candidate in the evolving field of precision oncology.
Clinical studies have demonstrated encouraging antitumor activity and a favorable safety profile, supporting continued late-stage development. The drug’s targeted mechanism offers the potential to deliver more effective and personalized treatment options for patients with biomarker-defined disease.
Global Regulatory Momentum and Future Outlook
Irpagratinib has already received multiple regulatory designations globally, including Fast Track Designation from the U.S. FDA and Breakthrough Therapy Designation from China’s NMPA, underscoring its strong clinical promise and global development momentum.
The ongoing pivotal registrational study of irpagratinib, involving more than 50 clinical research centers, reflects Abbisko’s commitment to advancing innovative therapies for oncology patients worldwide. These efforts are aligned with the growing trend toward biomarker-driven drug development, where therapies are tailored to specific genetic and molecular profiles.
With the EMA ODD now secured, Abbisko is well-positioned to accelerate clinical trials, engage with regulatory authorities, and prepare for future marketing authorization submissions, bringing the therapy closer to patients in need.
Advancing Precision Oncology in Liver Cancer
The EMA Orphan Drug Designation for irpagratinib represents a major advancement in targeted cancer therapy development, highlighting its potential to transform treatment options for patients with hepatocellular carcinoma. As clinical programs progress, irpagratinib could play a pivotal role in addressing unmet needs and improving outcomes in one of the most challenging oncology indications.
Source: Abbisko Therapeutics press release
